Icosapent Ethyl
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Icosapent Ethyl |
| DrugBank ID | DB08887 |
| Brand Names (EU) | Vazkepa |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 99.09% |
Approved Indication (EMA)
Indicated to reduce cardiovascular risk as an adjunct to statin therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hemoglobinopathy | 99.09% | DL |
| 2 | partial deletion of the short arm of chromosome 16 | 98.67% | DL |
| 3 | beta-thalassemia with other manifestations | 98.66% | DL |
| 4 | myocardial infarction | 98.60% | DL |
| 5 | hemolytic anemia due to glucophosphate isomerase deficiency | 98.55% | DL |
| 6 | pyruvate kinase deficiency of red cells | 98.44% | DL |
| 7 | pyropoikilocytosis, hereditary | 98.42% | DL |
| 8 | rheumatoid arthritis | 98.12% | DL |
| 9 | posterolateral myocardial infarction | 98.06% | DL |
| 10 | posteroinferior myocardial infarction | 98.06% | DL |
| 11 | septal myocardial infarction | 98.01% | DL |
| 12 | heart disease | 97.99% | DL |
| 13 | Jeune syndrome situs inversus | 97.92% | DL |
| 14 | Pierre Robin syndrome associated with a chromosomal anomaly | 97.86% | DL |
| 15 | pulmonary valve disease | 97.85% | DL |
| 16 | interventricular septum aneurysm | 97.85% | DL |
| 17 | orofacial clefting syndrome | 97.85% | DL |
| 18 | partial deletion of the long arm of chromosome 22 | 97.83% | DL |
| 19 | partial deletion of the long arm of chromosome 7 | 97.83% | DL |
| 20 | disorder of fucoglycosan synthesis | 97.83% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.